{
  "source": "PA-Med-Nec-Sunosi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2171-8\nProgram Prior Authorization/Medical Necessity\nMedication Sunosi® (solriamfetol)\nP&T Approval Date 7/2019, 8/2019, 8/2020, 8/2021, 8/2022, 9/2022, 11/2023, 9/2024\nEffective Date 12/1/2024\n1. Background:\nSunosi is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve\nwakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or\nobstructive sleep apnea (OSA).\nLimitations of Use: Sunosi is not indicated to treat the underlying airway obstruction in OSA.\nEnsure that the underlying airway obstruction is treated (e.g., with continuous positive airway\npressure (CPAP)) for at least one month prior to initiating Sunosi for excessive daytime\nsleepiness. Modalities to treat the underlying airway obstruction should be continued during\ntreatment with Sunosi. Sunosi is not a substitute for these modalities.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\n© 2024 UnitedHealthcare Services, Inc.\n1\nA. Narcolepsy\n1. Initial Authorization\na. Sunosi will be approved based on all of the following criteria:\n(1) Diagnosis of narcolepsy as confirmed by sleep study (unless the prescriber provides\njustification confirming that a sleep study would not be feasible)\n–AND–\n(2) Symptoms of excessive daytime sleepiness (including but not limited to daily periods of\nirrepressible need to sleep or daytime lapses into sleep) are present.\n–AND–\n(3) History of failure, contraindication, or intolerance to both of the following:\ni. One of the following:\n1. Amphetamine based stimulant (e.g., amphetamine, dextroamphetamine)\n2. Methylphenidate based stimulant\n–AND–\nii. One of the following:\n1. modafanil (Provigil)\n2. armodafanil (Nuvigil)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sunosi will be approved for continuation of therapy based on the following criterion:\n(1) Reduction in symptoms of excessive daytime slee",
    "horization will be issued for 12 months.\n2. Reauthorization\na. Sunosi will be approved for continuation of therapy based on the following criterion:\n(1) Reduction in symptoms of excessive daytime sleepiness associated with Sunosi therapy\nAuthorization will be issued for 12 months.\nB. Obstructive Sleep Apnea\n1. Initial Authorization\na. Sunosi will be approved based on all of the following criteria:\n(1) Diagnosis of obstructive sleep apnea defined by one of the following:\ni. Fifteen or more obstructive respiratory events per hour of sleep confirmed by a sleep\n© 2024 UnitedHealthcare Services, Inc.\n2\nstudy (unless the prescriber provides justification confirming that a sleep study would\nnot be feasible)\n–OR–\nii. Both of the following:\n1. Five or more obstructive respiratory events per hour of sleep confirmed by a\nsleep study (unless the prescriber provides justification confirming that a sleep\nstudy would not be feasible)\n–AND–\n2. One or more of the following signs/symptoms are present:\n(a) Daytime sleepiness\n(b) Nonrestorative sleep\n(c) Fatigue\n(d) Insomnia\n(e) Waking up with breath holding, gasping, or choking\n(f) Habitual snoring noted by bed partner or other observer\n(g) Observed apnea\n–AND–\n(2) Both of the following:\ni. Standard treatments for the underlying airway obstruction (e.g., continuous positive\nairway pressure [CPAP], bi-level positive airway pressure [BiPAP]) have been used\nfor one month or longer\n–AND–\nii. Patient is fully compliant with ongoing treatment(s) for the underlying airway\nobstruction\n–AND–\n(3) History of failure, contraindication, or intolerance to one of the following:\ni. armodafinil\nii. modafinil\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sunosi will be approved for continuation of therapy based on both the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n3\n(1) Reduction in symptoms of excessive daytime sleepiness associated with Sunosi therapy\n–AND–\n(2) Patient continues to be fully compliant with ongoing ",
    "teria:\n© 2024 UnitedHealthcare Services, Inc.\n3\n(1) Reduction in symptoms of excessive daytime sleepiness associated with Sunosi therapy\n–AND–\n(2) Patient continues to be fully compliant with ongoing treatment(s) for the underlying\nairway obstruction (e.g. CPAP, BiPAP)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit plan\ncoverage may also impact coverage criteria. Other policies and utilization management programs may\napply\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Sunosi [package insert]. New York, NY: Axsome Therapeutics, Inc; June 2023.\n2. American Academy of Sleep Medicine. International Classification of Sleep Disorders:\nDiagnostic and Coding Manual. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.\n3. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an\nAmerican 4. Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med.\n2021;17(9):1881–1893.\n4. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea\nin adults. J Clin Sleep Med. 2009;5(3):263-276.\nProgram Prior Authorization/Medical Necessity - Sunosi™ (solriamfetol)\nChange Control\n7/2019 New program\n8/2019 Changed from a trial of two previous medications to a trial of one in\nObstructive Sleep Apnea section.\n8/2020 Annual review with no changes to clinical coverage criteria. Updated\nreference.\n8/2021 Annual review with no changes to clinical coverage criteria. Updated\nreference formatting.\n8/2022 Annual review with no changes to clinical coverage criteria. Updated\nreferences.\n9/2022 Updated refe",
    "1 Annual review with no changes to clinical coverage criteria. Updated\nreference formatting.\n8/2022 Annual review with no changes to clinical coverage criteria. Updated\nreferences.\n9/2022 Updated references.\n11/2023 Annual review. Updated references.\n9/2024 Updated initial authorization to 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}